Andrew D.J. Pearson
YOU?
Author Swipe
View article: Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial Open
PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HR-NBL) remain dismal. Here, we investigate addition of the anti-GD2 monoclonal antibody, dinutuximab beta (dB), to temozolomide (T)-based chemotherapy.…
View article: International neuroblastoma risk group consortium: a model of networking for rare cancers
International neuroblastoma risk group consortium: a model of networking for rare cancers Open
It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve thi…
View article: Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum Open
High‐risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential c…
View article: Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration Open
Fewer than 10 % of children with diffuse midline glioma (DMG) survive 2 years from diagnosis. Radiation therapy remains the cornerstone of treatment and there are no medicinal products with regulatory approval. Although the biology of DMG …
View article: Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers
Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers Open
Importance In poor-prognosis children’s cancers, new therapies may carry fresh hope for patients and parents. However, there is an absolute requirement for any new therapy to be properly evaluated to fulfill scientific, regulatory, and rei…
View article: Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial Open
PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the anti…
View article: Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development Open
In a landscape of an increasing number of products and histology and age agnostic trials for rare patient cancer, prioritization of products is required. Paediatric Strategy Forums, organized by ACCELERATE and the European Medicines Agency…
View article: Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents Open
PURPOSE There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy …
View article: Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma Open
The dismal prognosis of glioblastoma (GB) indicates the urgent need for new therapies for these tumors. Heat shock protein 90 (HSP90) inhibitors induce the proteasome-mediated degradation of many oncogenic client proteins involved in all o…
View article: Supplementary Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Supplementary Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma Open
Supplementary Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
View article: Supplementary Table and Figures from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table and Figures from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table and Figures - PDF file 184K, Suppl Table S1: Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High level expression of p110del…
View article: Data from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors
Data from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors Open
Purpose: The cyclin-dependent kinase (CDK) 4/6 inhibitor, ribociclib (LEE011), displayed preclinical activity in neuroblastoma and malignant rhabdoid tumor (MRT) models. In this phase I study, the maximum tolerated dose (MTD) and recommend…
View article: CCR Translation for This Article from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
CCR Translation for This Article from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
CCR Translation for This Article from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
View article: Supplementary Figure 2 from Adaptive Dosing Approaches to the Individualization of 13-<i>Cis</i>-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
Supplementary Figure 2 from Adaptive Dosing Approaches to the Individualization of 13-<i>Cis</i>-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma Open
PDF file - 43K, Relationship between 13-cisRA AUC0-6h and 13-cisRA Cmax determined from pharmacokinetic profiles obtained following protocol-based 13-cisRA dosing (n=103)
View article: Data from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Data from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Purpose: To provide rationale for using phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway inhibitors to treat rhabdomyosarcomas, a major cause of pediatric and adolescent cancer deaths.Experimental Des…
View article: Data from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Data from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Purpose: To provide rationale for using phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway inhibitors to treat rhabdomyosarcomas, a major cause of pediatric and adolescent cancer deaths.Experimental Des…
View article: Data from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid Tumors
Data from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid Tumors Open
Purpose:The 2-part, phase I/IIa, open-label study (NCT01677741) sought to determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in pediatric patients with advanced BRAF V600–mutated cancers.Patients a…
View article: Supplementary Table & Figure Legends from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table & Figure Legends from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table & Figure Legends - PDF file 41K, Detailed captions for: Suppl Table S1. Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High …
View article: Supplementary Table & Figure Legends from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table & Figure Legends from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table & Figure Legends - PDF file 41K, Detailed captions for: Suppl Table S1. Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High …
View article: Supplementary Table and Figures from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table and Figures from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Table and Figures - PDF file 184K, Suppl Table S1: Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High level expression of p110del…
View article: Table S5 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid Tumors
Table S5 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid Tumors Open
Adverse events, suspected to be study drug related, reported by primary system organ class
View article: Data from Adaptive Dosing Approaches to the Individualization of 13-<i>Cis</i>-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
Data from Adaptive Dosing Approaches to the Individualization of 13-<i>Cis</i>-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma Open
Purpose: To investigate the feasibility of adaptive dosing and the impact of pharmacogenetic variation on 13-cis-retinoic acid (13-cisRA) disposition in high-risk patients with neuroblastoma.Experimental Design: 13-cisRA (160 mg/m2 or 5.33…
View article: Supplementary Methods from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Methods from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
Supplementary Methods - PDF file 44K, Method for the preparation and analysis of AZD8055, AZD6244 and BEZ235 by LC-MS/MS Drug-drug interaction assay
View article: Data from EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
Data from EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines Open
Purpose: The epidermal growth factor receptor (EGFR) is amplified and overexpressed in adult glioblastoma, with response to targeted inhibition dependent on the underlying biology of the disease. EGFR has thus far been considered to play a…
View article: Supplementary Data from EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
Supplementary Data from EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines Open
Supplementary Data from EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
View article: Supplementary Figure 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Supplementary Figure 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study Open
Supplementary Figure 1. Examples of changes observed in M30/M65 profiles as a function of dosing of AT9283 in two selected patients. Pt. 58/032 from cohort 4 (14.5 mg/m2/day) and Pt. 31/030 from cohort 6 (23 mg/m2/day).
View article: Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Data from Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma Open
The dismal prognosis of glioblastoma (GB) indicates the urgent need for new therapies for these tumors. Heat shock protein 90 (HSP90) inhibitors induce the proteasome-mediated degradation of many oncogenic client proteins involved in all o…